Clinical Trial

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Study acronym: SPARKLE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-04-22; most recent amendment 2024-07-01.
Status change: Active, Not Recruiting → Recruiting 2022-05-03
Trial Details
NCT Number NCT05352178
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Disease, Oligometastasis, Hormone Sensitive Prostate Cancer
Enrollment 873 participants
Start Date 2022-04-20
Primary Completion 2027-04-25 (estimated)
Study Completion 2032-04-25 (estimated)
Updated on ClinicalTrials.gov 2024-07-03